Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults
Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M. Hsieh, Kevin O. McNerney, Rayne H. Rouce, Rebecca Gardner, Sara Ghorashian, Nirali N. Shah, Shannon L. Maude
Abstract
Our global survey reveals no cases of insertional mutagenesis following CAR T-cells in pediatric patients challenging concerns of secondary malignancy risk in this population.This underscores the safety of CAR T-cell therapy in this population, but ongoing surveillance required.
Topics & Concepts
MalignancyInsertional mutagenesisPopulationMedicineYoung adultPediatricsImmunologyOncologyInternal medicineBiologyGeneticsEnvironmental healthGeneGenomeCAR-T cell therapy researchVirus-based gene therapy researchViral Infectious Diseases and Gene Expression in Insects